tirzepatide and semaglutide peptide or small molecule Sciences tirzepatide: what researchers need to know before ordering Tirzepatide (TZP) is a 39-amino

Semaglutide is a widely used GLP-1 with a clear, provider-guided titration pathway

Study outcomes The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke, over a 4.5-year follow-up period, consistent with the SOUL trial

Was Losing Control of Obesity and Diabetes Centers for Disease Control and Prevention data shows: - Obesity prevalence crossed 43% heading into 2025 - Were projected to approach 50% by 2030 without intervention No healthcare system in the world can absorb that level of chronic disease burden

Cardiovascular Protection : Studies have shown that GLP-1/GIP receptor agonists can reduce the risk of major cardiovascular events, including heart attack and stroke